XTL Biopharmaceuticals (XTLB) Stock Overview
A biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
XTLB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
XTL Biopharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪2.37 |
| 52 Week High | ₪10.28 |
| 52 Week Low | ₪2.12 |
| Beta | 0.68 |
| 1 Month Change | -8.83% |
| 3 Month Change | -12.04% |
| 1 Year Change | -47.33% |
| 3 Year Change | -51.97% |
| 5 Year Change | -81.28% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| XTLB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | -0.2% | 3.3% |
| 1Y | -47.3% | 40.4% | 28.1% |
Return vs Industry: XTLB underperformed the US Biotechs industry which returned 46.8% over the past year.
Return vs Market: XTLB underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| XTLB volatility | |
|---|---|
| XTLB Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: XTLB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XTLB's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | Noam Band | www.xtlbio.com |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
XTL Biopharmaceuticals Ltd. Fundamentals Summary
| XTLB fundamental statistics | |
|---|---|
| Market cap | US$6.23m |
| Earnings (TTM) | -US$6.31m |
| Revenue (TTM) | US$968.00k |
Is XTLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XTLB income statement (TTM) | |
|---|---|
| Revenue | US$968.00k |
| Cost of Revenue | US$3.22m |
| Gross Profit | -US$2.25m |
| Other Expenses | US$4.05m |
| Earnings | -US$6.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0067 |
| Gross Margin | -232.85% |
| Net Profit Margin | -651.65% |
| Debt/Equity Ratio | -183.0% |
How did XTLB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 00:11 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
XTL Biopharmaceuticals Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |